Repros Therapeutics Inc. (NASDAQ:RPRX) will release its earnings data on Monday, August 14th.

Repros Therapeutics (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. On average, analysts expect Repros Therapeutics to post $-0.45 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Repros Therapeutics Inc. (NASDAQ RPRX) traded up 0.49% during midday trading on Monday, reaching $0.31. The company’s stock had a trading volume of 279,129 shares. Repros Therapeutics Inc. has a 52 week low of $0.29 and a 52 week high of $2.48. The firm has a 50 day moving average price of $0.42 and a 200-day moving average price of $0.88. The firm’s market cap is $8.29 million.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/07/repros-therapeutics-inc-rprx-scheduled-to-post-earnings-on-monday.html.

Separately, Laidlaw cut shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, July 21st.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Earnings History for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.